FDA Strengthens Warning on Drug Paxil
Posted on: Tuesday, 3 January 2006, 09:00 CST
FDA strengthens warning on drug Paxil
WASHINGTON The Food and Drug Administration is strengthening its warning that the antidepressant Paxil may be associated with birth defects, citing a new study that found increased risk of fetuses developing heart defects.
The FDA asked manufacturer GlaxoSmithKline to reclassify the drug, which goes by the generic name paroxetine, as a Category D drug for pregnant women. The classification means that studies in pregnant women have shown a risk to the fetus. However, the FDA said, the benefits of the drug may outweigh the risk to the fetus.
Two studies of pregnant women taking Paxil during their first trimester have shown their babies have heart defects 1 to two times a greater rate than the norm, the FDA said Thursday. It issued a previous warning in September.
The FDA is advising doctors not to prescribe Paxil to women in their first three months of pregnancy or planning to become pregnant, unless there are no other options.
Source: Advocate; Baton Rouge, La.
Related Articles
- Wyeth's CONBRIZA Approved in the European Union for Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
- FDA to Boost Suicide Risk Warnings
- Diabetes Drug Might Hike Heart Attack Risk
- Women More at Risk From Smoke
- HIV Testing Options Increase: A Grant Makes Possible More Testing in Tulsa for Women at High Risk.
- Canadian Troops' Afghan Mission Could Raise Terror Risk, Warns Expert
- US FDA Orders Viagra Maker Update Warning Label
- Obesity Can Lead to Brain Loss, Study Finds; Overweight Women Have Higher Risk of Dementia, Tissue Shrinkage
- FDA Accused of Silencing Vioxx Warnings
- Parkinson’s drug linked to heart disease risk factor
 |
 |
User Comments (0)
RSS Feeds